Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410

Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications.

Format

JPEG

Source

PRISM MarketView

Downloads